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114 A decade of living lobar lung transplantation: Recipient outcomes
Vaughn A. Starnes, MD, Michael E. Bowdish, MD, Marlyn S. Woo, MD,
Richard G. Barbers, MD, Felicia A. Schenkel, RN, Monica V. Horn, RN, Renzo Pessotto, MD,
Eric M. Sievers, MD, Craig J. Baker, MD, Robbin G. Cohen, MD, Ross M. Bremner, MD,
PhD, Winfield J. Wells, MD, and Mark L. Barr, MD, Los Angeles, Calif
Living lobar lung transplantation has been performed at our institution over the past 10 years in
123 recipients. Actuarial survival with this procedure is 70%, 54%, and 45% at 1, 3, and 5
years, respectively. Patients undergoing retransplantations and those intubated preoperatively
had worse outcomes. Living lobar lung transplantation remains a viable alternative for those
patients deemed unable to await cadaveric transplantation.
123 Immuno-gene therapy with interferon- before surgical debulking delays
recurrence and improves survival in a murine model of malignant
mesothelioma
Robert J. Kruklitis, MD, PhD, Sunil Singhal, MD, Peter Delong, MD, Veena Kapoor, BS,
Daniel H. Sterman, MD, Larry R. Kaiser, MD, and Steven M. Albelda, MD, Philadelphia, Pa
Immuno-gene therapy with Ad.IFN- can cure early-stage mesothelioma tumors in mice;
however, the therapy fails for bulky tumors. This study determined the mechanism for the loss
of efficacy in large tumors and demonstrated a novel approach combining preoperative
Ad.IFN- with surgical debulking to reduce tumor recurrence and improve long-term tumor-
free survival.
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131 Initial experience with the AbioCor Implantable Replacement Heart System
Robert D. Dowling, MD, Laman A. Gray, Jr, MD, Steven W. Etoch, MD, Hillel Laks, MD,
Daniel Marelli, MD, Louis Samuels, MD, John Entwistle, MD, Greg Couper, MD,
Gus J. Vlahakes, MD, and O. H. Frazier, MD, Louisville, Ky, Los Angeles, Calif,
Philadelphia, Pa, Houston, Tex, and Boston, Mass
The AbioCor Implantable Replacement Heart System is the first totally implantable artificial
heart system. We report the preliminary clinical experience with this device.
142 Equivalent midterm outcomes after off-pump and on-pump coronary
surgery
Joseph F. Sabik, MD, Eugene H. Blackstone, MD, Bruce W. Lytle, MD, Penny L. Houghtaling,
MS, A. Marc Gillinov, MD, and Delos M. Cosgrove, MD, Cleveland, Ohio
In propensity-matched patients undergoing off-pump and on-pump primary coronary artery
bypass grafting, midterm survival and freedom from myocardial infarction, percutaneous
coronary intervention, coronary reoperation, and the combined end point of all-cause mortality,
myocardial infarction, and all coronary reintervention were similar.
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